Literature DB >> 3095232

Both Fc alpha domains of human IgA are involved in in vitro interaction between secretory component and dimeric IgA.

C Geneste, S Iscaki, R Mangalo, J Pillot.   

Abstract

The sites of interaction between 125I labelled human secretory component (SC) and dimeric IgA were located by studying the inhibitory effect of various antibodies to IgA. Several Fab' fragments were isolated from three sera of hyperimmunized rabbits. The specificity of these different antibody preparations, as determined by a RIA inhibition test or by ELISA, showed that two were directed against both domains of Fc alpha, two against C alpha 2, two against C alpha 3 and one against Fd alpha. A monoclonal antibody against C alpha 3 was also used. The results indicate that both the C alpha 2 and C alpha 3 domains are equally and independently involved in the interaction between SC and dimeric IgA.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3095232     DOI: 10.1016/0165-2478(86)90105-7

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  4 in total

Review 1.  The structure and function of human IgA.

Authors:  M A Kerr
Journal:  Biochem J       Date:  1990-10-15       Impact factor: 3.857

2.  Sjögren syndrome: comparative studies in local ocular and serum immunoglobulin concentrations with special reference to secretory IgA.

Authors:  A Wehmeyer; P K Das; T Swaak; W Gebhart; A Kijlstra
Journal:  Int Ophthalmol       Date:  1991-05       Impact factor: 2.031

3.  IgA and IgA-specific receptors in human disease: structural and functional insights into pathogenesis and therapeutic potential.

Authors:  Michelle M Gomes; Andrew B Herr
Journal:  Springer Semin Immunopathol       Date:  2006-10-17

4.  Sequence of the dog immunoglobulin alpha and epsilon constant region genes.

Authors:  M Patel; D Selinger; G E Mark; G J Hickey; G F Hollis
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.